• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迟发性运动障碍的筛查、诊断和治疗的德尔菲共识研究的改良版。

A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia.

机构信息

Corporal Michael J. Crescenz Veterans Affairs Medical Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104.

Corporal Michael J. Crescenz Veterans Affairs Medical Center and Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

出版信息

J Clin Psychiatry. 2020 Jan 28;81(2):19cs12983. doi: 10.4088/JCP.19cs12983.

DOI:10.4088/JCP.19cs12983
PMID:31995677
Abstract

OBJECTIVE

A nominal group process followed by a modified Delphi method was used to survey expert opinions on best practices for tardive dyskinesia (TD) screening, diagnosis, and treatment and to identify areas lacking in clinical evidence.

PARTICIPANTS

A steering committee of 11 TD experts met in nominal group format to prioritize questions to be addressed and identify core bibliographic materials and criteria for survey panelists. Of 60 invited experts, 29 (23 psychiatrists and 6 neurologists) agreed to participate.

EVIDENCE

A targeted literature search of PubMed (search term: tardive dyskinesia) and recommendations of the steering committee were used to generate core bibliographic material. Inclusion criteria were as follows: (1) review articles, meta-analyses, guidelines, or clinical trials; (2) publication in English between 2007 and 2017; (3) > 3 pages in length; and (4) publication in key clinical journals with impact factors ≥ 2.0. Of 29 references that met these criteria, 18 achieved a score ≥ 5 (calculated as the number of steering committee votes multiplied by journal impact factor and number of citations divided by years since publication) and were included.

CONSENSUS PROCESS

Two survey rounds were conducted anonymously through electronic media from November 2017 to January 2018; responses were collected, collated, and analyzed. Respondent agreement was defined a priori as unanimous (100%), consensus (75%-99%), or majority (50%-74%). For questions using a 5-point Likert scale, agreement was based on percentage of respondents choosing ≥ 4 ("agree completely" or "agree"). Round 1 survey included questions on TD screening, diagnosis, and treatment. Round 2 questions were refined per panelist feedback and excluded Round 1 questions with < 25% agreement and > 75% agreement (unless feedback suggested further investigation).

CONCLUSIONS

Consensus was reached that (1) a brief, clinical assessment for TD should be performed at every clinical encounter in patients taking antipsychotics; (2) even mild movements in 1 body area may represent possible TD; (3) management requires an overall evaluation of treatment, including reassessment of antipsychotics and anticholinergics as well as consideration of vesicular monoamine transporter 2 (VMAT2) inhibitors; and (4) informed discussions with patients/caregivers are essential.

摘要

目的

采用名义群体法和改良 Delphi 法调查专家对迟发性运动障碍(TD)筛查、诊断和治疗最佳实践的意见,并确定临床证据不足的领域。

参与者

一个由 11 名 TD 专家组成的指导委员会以名义群体的形式开会,确定需要解决的问题的优先级,并确定调查小组成员的核心文献资料和标准。在 60 名受邀专家中,有 29 名(23 名精神科医生和 6 名神经科医生)同意参与。

证据

对 PubMed 的针对性文献检索(搜索词:迟发性运动障碍)和指导委员会的建议用于生成核心文献资料。纳入标准如下:(1)综述文章、荟萃分析、指南或临床试验;(2)2007 年至 2017 年期间以英文发表;(3)长度超过 3 页;(4)在影响因子≥2.0 的主要临床期刊上发表。符合这些标准的 29 篇参考文献中,有 18 篇得分≥5(计算方法为指导委员会投票数乘以期刊影响因子和引用数除以发表年限),被纳入研究。

共识过程

2017 年 11 月至 2018 年 1 月,通过电子媒体匿名进行了两轮调查;收集、整理和分析了答复。事先定义了应答者的一致性为一致(100%)、共识(75%-99%)或多数(50%-74%)。对于使用 5 分李克特量表的问题,一致性基于选择≥4(“完全同意”或“同意”)的应答者的百分比。第一轮调查包括关于 TD 筛查、诊断和治疗的问题。根据小组成员的反馈,第二轮问题进行了细化,并排除了第一轮中<25%的一致性和>75%的一致性的问题(除非反馈表明需要进一步调查)。

结论

专家组达成一致意见,即(1)在服用抗精神病药物的患者每次临床就诊时,都应进行简短的 TD 临床评估;(2)即使只有一个身体部位的轻微运动也可能代表可能的 TD;(3)管理需要对治疗进行全面评估,包括重新评估抗精神病药物和抗胆碱能药物,以及考虑使用囊泡单胺转运体 2(VMAT2)抑制剂;(4)与患者/照顾者进行知情讨论至关重要。

相似文献

1
A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia.迟发性运动障碍的筛查、诊断和治疗的德尔菲共识研究的改良版。
J Clin Psychiatry. 2020 Jan 28;81(2):19cs12983. doi: 10.4088/JCP.19cs12983.
2
Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.治疗迟发性运动障碍的药物选择和临床策略。
J Clin Psychiatry. 2020 Jan 28;81(2):TV18059BR2C. doi: 10.4088/JCP.TV18059BR2C.
3
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.用丁苯那嗪或缬苯那嗪治疗迟发性运动障碍:一项系统评价
J Comp Eff Res. 2018 Feb;7(2):135-148. doi: 10.2217/cer-2017-0065. Epub 2017 Oct 2.
4
Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.抗精神病药所致迟发性运动障碍:从生物学基础到临床管理。
Expert Rev Neurother. 2017 Sep;17(9):883-894. doi: 10.1080/14737175.2017.1361322. Epub 2017 Aug 3.
5
Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.迟发性运动障碍的流行病学、预防、评估及治疗进展
J Clin Psychiatry. 2017 Sep/Oct;78(8):1136-1147. doi: 10.4088/JCP.tv17016ah4c.
6
Valbenazine for the treatment of tardive dyskinesia.用于治疗迟发性运动障碍的氘代丁苯那嗪
Expert Opin Pharmacother. 2017 Aug;18(12):1279-1287. doi: 10.1080/14656566.2017.1353078. Epub 2017 Aug 2.
7
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.缬苯那嗪(NBI-98854)治疗迟发性运动障碍合并精神分裂症或分裂情感性障碍患者的疗效。
Psychopharmacol Bull. 2017 Aug 1;47(3):69-76.
8
[Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].抗精神病药物所致迟发性运动障碍的防治
Encephale. 2016 Jun;42(3):248-54. doi: 10.1016/j.encep.2015.12.021. Epub 2016 Feb 26.
9
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.缬苯那嗪(NBI-98854)治疗迟发性运动障碍和情绪障碍患者的疗效。
Psychopharmacol Bull. 2017 Aug 1;47(3):53-60.
10
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.迟发性运动障碍的治疗:概述及重点关注囊泡单胺转运体 2 抑制剂。
Drugs. 2018 Apr;78(5):525-541. doi: 10.1007/s40265-018-0874-x.

引用本文的文献

1
Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway.亚洲的迟发性运动障碍——当前临床实践及神经科医生在护理流程中的作用
Front Neurol. 2024 Feb 14;15:1356761. doi: 10.3389/fneur.2024.1356761. eCollection 2024.
2
Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia.亨廷顿病或迟发性运动障碍患者中持续使用和坚持使用氘代丁苯那嗪的预测因素。
Ment Health Clin. 2023 Oct 2;13(5):207-216. doi: 10.9740/mhc.2023.10.207. eCollection 2023 Oct.
3
Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.
潜在迟发性运动障碍对身体健康和社会功能的影响:真实世界RE-KINECT研究的结果
J Patient Rep Outcomes. 2023 Mar 9;7(1):21. doi: 10.1186/s41687-023-00551-5.
4
Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan.迟发性运动障碍的流行病学和负担的当前观点:对日本临床情况的重点综述
Ther Adv Psychopharmacol. 2022 Dec 26;12:20451253221139608. doi: 10.1177/20451253221139608. eCollection 2022.
5
Clinician Perceptions of the Negative Impact of Telehealth Services in the Management of Drug-Induced Movement Disorders and Opportunities for Quality Improvement: A 2021 Internet-Based Survey.临床医生对远程医疗服务在药物性运动障碍管理中的负面影响及质量改进机会的看法:一项2021年基于互联网的调查。
Neuropsychiatr Dis Treat. 2022 Dec 19;18:2945-2955. doi: 10.2147/NDT.S385960. eCollection 2022.
6
Telehealth for Assessing and Managing Tardive Dyskinesia: Expert Insights from a Cross-Disciplinary Virtual Treatment Panel.远程医疗评估和管理迟发性运动障碍:跨学科虚拟治疗小组的专家见解。
Telemed J E Health. 2023 Jul;29(7):1096-1104. doi: 10.1089/tmj.2022.0234. Epub 2022 Dec 14.
7
Treatment patterns and unmet needs in adults with classic congenital adrenal hyperplasia: A modified Delphi consensus study.经典型先天性肾上腺皮质增生症成人患者的治疗模式和未满足的需求:一项改良 Delphi 共识研究。
Front Endocrinol (Lausanne). 2022 Nov 18;13:1005963. doi: 10.3389/fendo.2022.1005963. eCollection 2022.
8
Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations.临床实践中迟发性运动障碍影响的评估:共识小组建议
Neuropsychiatr Dis Treat. 2021 May 24;17:1589-1597. doi: 10.2147/NDT.S310605. eCollection 2021.
9
CO-aVoID: coronavirus outbreak affecting variability of presentations to a local emergency department.CO-aVoID:冠状病毒爆发对当地急诊就诊表现的变异性的影响。
CJEM. 2021 Mar;23(2):232-236. doi: 10.1007/s43678-020-00036-0. Epub 2021 Jan 4.
10
Recent Advances in the Pharmacology of Tardive Dyskinesia.迟发性运动障碍药理学的最新进展
Clin Psychopharmacol Neurosci. 2020 Nov 30;18(4):493-506. doi: 10.9758/cpn.2020.18.4.493.